Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Currency in USD	2025
Operating Income	633.00 Million
Income Before Tax	519.00 Million
Income Tax Expense	112.00 Million
Net Income	402.00 Million
Eps	1.82
Epsdiluted	1.81
Weighted Average Shs Out	220.59 Million
Weighted Average Shs Out Dil	222.68 Million
Depreciation And Amortization	238.00 Million
Interest Expense	88.00 Million
Ebit	607.00 Million
Interest Income	6.00 Million
Net Interest Income	-91 Million
Period	FY
Ebitda	871.00 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

Hikma Pharmaceuticals PLC Annual Reports (10-K)